Analysten nachrichten

IRLAB’s Phase IIb Study with Pirepemat Passes DSMB Safety Review with Unanimous Recommendation to Continue the Ongoing Phase IIb Study

External page is loading, the page should display in a few seconds..

    Follow @AnalystenNews on Twitter!